We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Episodic Breathlessness in Patients With Lung Cancer or Other Advanced Disease

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01138358
First Posted: June 7, 2010
Last Update Posted: August 26, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
National Cancer Institute (NCI)
June 4, 2010
June 7, 2010
August 26, 2013
January 2010
August 2010   (Final data collection date for primary outcome measure)
  • Experiences of episodic breathlessness
  • Impact of episodic breathlessness on daily living
  • Individual coping strategies to reduce burden of episodic breathlessness
Same as current
Complete list of historical versions of study NCT01138358 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Study of Episodic Breathlessness in Patients With Lung Cancer or Other Advanced Disease
Experiences of Episodic Breathlessness (EB) in Patients With Advanced Disease

RATIONALE: Gathering information about experiences of episodic breathlessness in patients with advanced disease may help doctors learn more about the disease.

PURPOSE: This clinical trial is studying experiences of episodic breathlessness in patients with lung cancer or other advanced disease.

OBJECTIVES:

  • To explore the experiences of episodic breathlessness in patients with advanced disease (i.e., primary and secondary lung cancer, chronic obstructive pulmonary disease [COPD], chronic heart failure [CHF], and motor neuron disease [MND]).
  • To explore the impact of episodic breathlessness on daily living.
  • To explore the individual coping strategies to reduce burden of episodic breathlessness.

OUTLINE: This is a multicenter study.

Patients undergo 1 to 2 interviews to collect data on experiences of breathlessness (in general, at rest, and on exertion including symptom description, interpretation, and meaning); experiences of episodic breathlessness (EB) (at rest and on exertion including symptom description, interpretation, meaning, and definition); trajectory/course of EB (onset/relief, time, and severity) and different types/trajectories of EB; impact of EB (burden, emotional reaction [panic and fear], care burden, and dependencies); triggers of EB (causes, situation, and settings) and predictability of EB; management of EB (coping strategies, non-pharmacological and pharmacological management [including different applications], worsen/relief, role of care in coping, and emotional/behavior strategies; views on and experiences with services/professionals in management of EB and response to professional advice; and attitudes towards the future, course of the disease, and awareness of prognosis. At the end of the interview, the patient will be asked to draw a figure that illustrates the trajectory of the episode. After the interview, a debriefing will be carried out to give the patient the chance to express worries, potential harm, or any comments about the interview. In addition to the interviews, further information will be collected including demographics, diagnosis and co-morbidities, current pharmacological and non-pharmacological treatments (medical history), functional status (Karnofsky), and breathlessness characteristics (e.g., intensity, frequency, and duration). The interviews will be tape-recorded, transcribed verbatim, and analyzed concurrently using Framework Approach.

Observational
Not Provided
Not Provided
Not Provided
Not Provided
Not Provided
  • Dyspnea
  • Lung Cancer
  • Metastatic Cancer
  • Other: medical chart review
  • Other: study of socioeconomic and demographic variables
  • Other: survey administration
  • Procedure: quality-of-life assessment
Not Provided
Simon ST, Niemand AM, Benalia H, Voltz R, Higginson IJ, Bausewein C. Acceptability and preferences of six different routes of drug application for acute breathlessness: a comparison study between the United Kingdom and Germany. J Palliat Med. 2012 Dec;15(12):1374-81. doi: 10.1089/jpm.2012.0249. Epub 2012 Oct 24.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
October 2012
August 2010   (Final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Diagnosis of advanced disease as defined by the following criteria:

    • Lung cancer

      • Primary lung cancer at all stages (small cell lung cancer [SCLC] and non-small cell lung cancer [NSCLC])
      • Cancer at any site with secondary tumor of the lung (lung metastasis)
    • Chronic obstructive pulmonary disease (COPD)

      • Stage III or IV of the Global Initiative for Obstructive Lung Disease (GOLD) classification, which includes the airflow limitation measured by spirometry FEV1 < 50%, FEV1/FVC < 0.7, and symptoms such as more severe breathlessness, reduced exercise capacity, and repeated exacerbations
    • Chronic heart failure (CHF)

      • NYHA class II-IV heart disease, which includes symptoms such as dyspnea or palpitation and an increasing limitation of exercise capacity or discomfort at rest
    • Motor neuron disease (MND)

      • All patients suffering from breathlessness
  • Suffering from episodic breathlessness as defined above at any level of severity

PATIENT CHARACTERISTICS:

  • Able to give informed consent
  • Able to be interviewed
  • No cognitive impairment (clinically judged by the principal investigator)
  • No limited comprehension of the English language

PRIOR CONCURRENT THERAPY:

  • Concurrent disease-oriented therapies (e.g., chemotherapy, radiotherapy, or surgery) allowed
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
 
NCT01138358
CDR0000674580
UKM-KCH-EB-V4
EU-21039
Not Provided
Not Provided
Not Provided
Not Provided
King's College Hospital NHS Trust
Not Provided
Principal Investigator: Steffen Simon, MD, MSC King's College Hospital NHS Trust
National Cancer Institute (NCI)
June 2010